Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ladarixin - Dompe Farmaceutici

Drug Profile

Ladarixin - Dompe Farmaceutici

Alternative Names: DF-2156A; DF-2156Y; LDX - Dompe Farmaceutici; Meraxin

Latest Information Update: 18 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dompe Farmaceutici
  • Class Antihyperglycaemics; Small molecules; Sulfonamides
  • Mechanism of Action Interleukin 8A receptor antagonists; Interleukin 8B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Type 1 diabetes mellitus
  • Phase II Insulin resistance
  • Discontinued Bullous pemphigoid; Malignant melanoma; Spinal cord injuries

Most Recent Events

  • 08 Mar 2024 Dompe Farmaceutici terminates a phase II trial in Insulin resistance in Italy (PO, Capsule) (EudraCT2020-003296-18)
  • 28 Nov 2023 No recent reports of development identified for phase-I development in Type-1 diabetes mellitus(In volunteers) in Switzerland (PO, Capsule)
  • 07 Nov 2023 Dompe Farmaceutici terminates a phase-II clinical trials in Type 1 diabetes mellitus (Adjunctive treatment) in the Italy (PO) due to low recruitment rate (NCT05368402) (EudraCT2022-000743-68)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top